The estimated Net Worth of Ronald E Blaylock is at least 4.49 百万$ dollars as of 16 July 2021. Mr. Blaylock owns over 12,500 units of Pfizer stock worth over 173,630$ and over the last 17 years he sold PFE stock worth over 3,966,533$. In addition, he makes 350,000$ as Independent Director at Pfizer.
Sign up
Mr. Blaylock PFE stock SEC Form 4 insiders trading
Ronald has made over 11 trades of the Pfizer stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 12,500 units of PFE stock worth 1,650,250$ on 16 July 2021.
The largest trade he's ever made was buying 13,000 units of Pfizer stock on 6 August 2020 worth over 501,150$. On average, Ronald trades about 1,369 units every 64 days since 2008. As of 16 July 2021 he still owns at least 5,854 units of Pfizer stock.
You can see the complete history of Mr. Blaylock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Blaylock biography
Ronald E. Blaylock serves as Independent Director of the Company. Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. He also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of CarMax, Inc., W.R. Berkley, Corporation, an insurance holding company, and Conyers Park II Acquisition Corp. (a special purpose acquisition company and an affiliate of Centerview Capital). Director of Syncreon U.S., a for-profit private company. Former Director of Urban One, Inc. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. Board Member of Mebane Foundation.
What is the salary of Ronald Blaylock?
As the Independent Director of Pfizer, the total compensation of Ronald Blaylock at Pfizer is 350,000$. There are 15 executives at Pfizer getting paid more, with Albert Bourla having the highest compensation of 17,929,000$.
How old is Ronald Blaylock?
Ronald Blaylock is 60, he's been the Independent Director of Pfizer since 2017. There are 10 older and 19 younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.
What's Ronald Blaylock's mailing address?
Ronald's mailing address filed with the SEC is 12800 TUCKAHOE CREEK PKWY, , RICHMOND, VA, 23238.
Insiders trading at Pfizer
Over the last 12 years, insiders at Pfizer have traded over 216,003,942$ worth of Pfizer stock and bought 24,324 units worth 872,198$ . The most active insiders traders include Shantanu Narayen、Ian C Read、James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of 2,169,896$. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth 147,714$.
What does Pfizer do?
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
What does Pfizer's logo look like?
Complete history of Mr. Blaylock stock trades at Carmax Inc、Pfizer、W.R. Berkley
Pfizer executives and stock owners
Pfizer executives and other stock owners filed with the SEC include:
-
Albert Bourla,
Chairman of the Board, Chief Executive Officer -
Frank D'Amelio,
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply -
Mikael Dolsten,
Chief Scientific Officer, President - Worldwide Research, Development and Medical -
John Young,
Chief Business Officer, Group President -
Dr. Albert Bourla D.V.M., DVM, Ph.D.,
Chairman & CEO -
Frank A. D'Amelio,
CFO & Exec. VP -
Dr. Mikael Dolsten M.D., Ph.D.,
Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical -
Angela Hwang,
Group Pres of Biopharmaceuticals Group -
John D. Young,
Advisor -
Shantanu Narayen,
Lead Independent Director -
Wyllie Don Cornwell,
Independent Director -
Helen Hobbs,
Independent Director -
Suzanne Nora Johnson,
Independent Director -
Joseph Echevarria,
Independent Director -
James Kilts,
Independent Director -
Ronald Blaylock,
Independent Director -
Dan Littman,
Independent Director -
Scott Gottlieb,
Independent Director -
James Quincey,
Independent Director -
Susan Hockfield,
Independent Director -
Susan Desmond-Hellmann,
Director -
Gordon Loh,
Senior Vice President, Corporate Audit -
Jennifer Damico,
Senior Vice President, Principal Accounting Officer, Controller -
Sally Susman,
Chief Corporate Affairs Officer, Executive Vice President -
Alexander Mackenzie,
Executive Vice President, Chief Development Officer -
Douglas Lankler,
Executive Vice President, General Counsel -
Rady Johnson,
Chief Compliance, Quality and Risk Officer, Executive Vice President -
Lidia Fonseca,
Executive Vice President, Chief Technology Officer and Digital Officer -
Dawn Rogers,
Chief Human Resource Officer, Executive Vice President -
Angela Hwang,
Group President, Pfizer Biopharmaceuticals Group -
Rady A. Johnson,
Exec. VP and Chief Compliance, Quality & Risk Officer -
Douglas M. Lankler,
Exec. VP & Gen. Counsel -
Christopher J. Stevo CFA,
Sr. VP & Chief Investor Relations Officer -
Lidia L. Fonseca,
Exec. VP and Chief Digital & Technology Officer -
Jennifer B. Damico,
Sr. VP, Controller & Principal Accounting Officer -
Mike McDermott,
Chief Financial Officer -
William Pao,
Executive Vice President -
Stephen W Sanger,
Director -
Frances D Fergusson,
Director -
James C Smith,
Director -
Laurie J Olson,
Executive Vice President -
W Don Cornwell,
Director -
Loretta V Cangialosi,
Sr. Vice President, Controller -
Charles H Hill,
Executive Vice President -
Dennis A Ausiello,
Director -
Kirsten Lund Jurgensen,
Executive Vice President -
Ian C Read,
Chairman & CEO -
Freda C Lewis Hall,
Executive Vice President -
Aamir Malik,
Executive Vice President -
Christoffel Boshoff,
Executive Vice President -
Michael Goettler,
Group President -
Cyrus Taraporevala,
Director -
Iii William H Gray,
Director -
M Anthony Burns,
Director -
Cavan M. Redmond,
Group President -
Kristin C Peck,
Executive Vice President -
David S Simmons,
Business Unit President -
Geno J Germano,
Business Unit President -
Anthony J Maddaluna,
Executive Vice President -
Olivier Brandicourt,
Business Unit President -
Marc Tessier Lavigne,
Director -
George A Lorch,
Director -
Amy W Schulman,
Executive Vice President -
Constance J Horner,
Director -
Payal Sahni,
Executive Vice President -
William R Jr Carapezzi,
Executive Vice President -
Michael Mc Dermott,
Executive Vice President -
David M Denton,
Chief Financial Officer & EVP